Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07498517 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT
A Phase 2 study, sponsored by OHSU Knight Cancer Institute.
- Not yet
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT07498517 is a Phase 2 study that has not yet begun recruiting, run by OHSU Knight Cancer Institute. The registered enrollment target is 90 participants.
The verdict
NCT07498517, a Phase 2 study, has not yet begun recruiting, sponsored by OHSU Knight Cancer Institute.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This phase II trial studies how well gruticibart works in reducing the incidence of catheter-related thrombosis (CRT) blood clots in patients with a central venous catheter (CVC) inserted. Many patients develop blood clots from their catheters and can have pain, swelling, and other symptoms. They also often require blood thinners, which can increase the risk of bleeding. Gruticibart, a type of drug called a monoclonal antibody, may prevent blood clots caused by a catheter.
Interventions
- DRUG Placebo
- PROCEDURE Ultrasound
- DRUG Gruticibart
- PROCEDURE Biopspecimen collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-02-28 |
| Est. Completion | 2029-10-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07498517
The ClinicalTrials.gov registry entry for NCT07498517 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT07498517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07498517 about?
NCT07498517 is a clinical study titled "Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT". This phase II trial studies how well gruticibart works in reducing the incidence of catheter-related thrombosis (CRT) blood clots in patients with a central venous catheter (CVC) inserted. Many patients develop blood clots from their catheters and can have pain, swelling, and other symptoms. They al...
What is the current status of trial NCT07498517?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2026-02-28. Estimated completion is 2029-10-02.
What interventions are being tested in trial NCT07498517?
The interventions under investigation include: Placebo (DRUG), Ultrasound (PROCEDURE), Gruticibart (DRUG), Biopspecimen collection (PROCEDURE).
Who is sponsoring clinical trial NCT07498517?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.